DUSP6 inhibition overcomes Neuregulin/HER3-driven therapy resistance in HER2+ breast cancer [BT474]

To investigate transcriptomic changes during development of resistance to lapatinib in a HER2+ breast cancer cell line We performed gene expression profiling analysis using data obtained from RNA-seq of 4 different stage of development of lapatinib resistance in a HER2+ breast cancer cell line Overall design: Comparative gene expression profiling analysis of RNA-seq data in parental drug sensitive, drug tolerant persister, drug tolerant expanding persister and longtem resistant cells